Hyderabad based Natco Pharma Limited has reported consolidated revenue of Rs. 827.90 crore and Rs. 203.90 crore PAT (Profit After Tax) for the second quarter FY 2020-21. 

 

NATCO Pharma has recorded consolidated total revenue of Rs. 827.90 crore for the second quarter ended on 30th September, 2020 as against Rs. 518.90 crore for the same period last year, reflecting a growth of 59.5%. 

 

The net profit for the period on a consolidated basis was Rs. 203.90 crore as against Rs. 117.7 crore in the same period last year, showing a growth of 73.2%.

 

The Board of Directors has recommended a second interim dividend of Rs. 3 per equity share of Rs. 2 each for FY 2020-21.